Background/Aims/Objectives: To evaluate the influence of body mass index (BMI) on complications and oncological outcomes in patients undergoing radical cystectomy (RC). Methods: Clinical and histopathological parameters of patients have been prospectively collected within the “PROspective MulticEnTer RadIcal Cystectomy Series 2011”. BMI was categorized as normal weight (<25 kg/m2), overweight (≥25–29.9 kg/m2) and obesity (≥30 kg/m2). The association between BMI and clinical and histopathological endpoints was examined. Ordinal logistic regression models were applied to assess the influence of BMI on complication rate and survival. Results: Data of 671 patients were eligible for final analysis. Of these patients, 26% (n = 175) showed obesity. No significant association of obesity on tumour stage, grade, lymph node metastasis, blood loss, type of urinary diversion and 90-day mortality rate was found. According to the -American Society of Anesthesiologists score, local lymph node (NT) stage and operative case load patients with higher BMI had significantly higher probabilities of severe complications 30 days after RC (p = 0.037). The overall survival rate of obese patients was superior to normal weight patients (p = 0.019). Conclusions: There is no evidence of correlation between obesity and worse oncological outcomes after RC. While obesity should not be a parameter to exclude patients from cystectomy, surgical settings need to be aware of higher short-term complication risks and obese patients should be counselled -accordingly.

Keywords:
Urothelial carcinoma, Bladder cancer, Obesity, Radical cystectomy, Prognosis, Survival
1.
Wang Y, Beydoun MA: The obesity epidemic in the United States – gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007; 29: 6–28.
2.
Mullen JT, Davenport DL, Hutter MM, Hosokawa PW, Henderson WG, Khuri SF, et al: Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. Ann Surg Oncol 2008; 15: 2164–2172.
3.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.
4.
Møller H, Mellemgaard A, Lindvig K, Olsen JH: Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344–350.
5.
Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, et al: Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 2005; 93: 1062–1067.
6.
Wolk A, Gridley G, Svensson M, Nyrèn O, McLaughlin JK, Fraumeni JF, et al: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13–21.
7.
Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P: Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int 2010; 105: 16–20.
8.
Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D: The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control 2010; 17: 52–57.
9.
Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, et al; Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the shared equal access regional cancer hospital and duke prostate center database. BJU Int 2008; 102: 969–974.
10.
Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al: Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 2008; 123: 2188–2194.
11.
Lee CT, Dunn RL, Chen BT, Joshi DP, Sheffield J, Montie JE: Impact of body mass index on radical cystectomy. J Urol 2004; 172: 1281–1285.
12.
Chang SS, Jacobs B, Wells N, Smith JA Jr, Cookson MS: Increased body mass index predicts increased blood loss during radical cystectomy. J Urol 2004; 171: 1077–1079.
13.
Abern MR, Freedland SJ, Inman BA: Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int 2013; 111: 187–198.
14.
Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, et al; Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int 2013; 111: 249–255.
15.
Kwon T, Jeong IG, You D, Han KS, Hong S, Hong B, et al: Obesity and prognosis in ­muscle-invasive bladder cancer: the continuing controversy. Int J Urol 2014; 21: 1106–1112.
16.
Hafron J, Mitra N, Dalbagni G, Bochner B, Herr H, Donat SM: Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol 2005; 173: 1513–1517.
17.
Maurer T, Maurer J, Retz M, Paul R, Zantl N, Gschwend JE, et al: Influence of body mass index on operability, morbidity and disease outcome following radical cystectomy. Urol Int 2009; 82: 432–439.
18.
Bagrodia A, Grover S, Srivastava A, Gupta A, Bolenz C, Sagalowsky Al, et al: Impact of body mass index on clinical and cost outcomes after radical cystectomy. BJU Int 2009; 104: 326–330.
19.
Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, et al: Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol 2014; 66: 156–163.
20.
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al: The American Joint Committee on Cancer (AJCC) Staging Manual (ed 7). Philadelphia, Springer, 2009.
21.
Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumours. Geneva, World Health Organization, 1973.
22.
Novotny V, Hakenberg OW, Wiessner D, Heberling U, Litz RJ, Oehlschlaeger S, et al: Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 2007; 51: 397–401.
23.
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, et al: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012; 61: 854–865.
24.
Mayr R, May M, Martini T, Lodde M, Pycha A, Comploj E, et al: Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int 2012; 110(6 pt B): E222–E227.
25.
Tyson MD, Humphreys MR, Castle EP: Obese patients undergoing cystectomy: a population-based, propensity score matched analysis. Int J Urol 2014; 21: 491–495.
26.
Roghmann F, Trinh QD, Braun K, von Bodman C, Brock M, Noldus J, et al: Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. Int J Urol 2014; 21: 143–149
27.
Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, et al: Predictors of postoperative complications in patients who undergo radical nephrectomy and IVC thrombectomy: a large contemporary tertiary center analysis. Clin Genitourin Cancer 2016; 14: 89–95.
28.
Kastanis G, Topalidou A, Alpantaki K, Rosiadis M, Balalis K: Is the ASA score in geriatric hip fractures a predictive factor for complications and readmission? Scientifica (Cairo) 2016; 2016: 7096245.
29.
Mani J, Vallo S, Brandt MP, Gust KM, Bartsch C, Daechert J, et al; What should be the patient’s preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital. Patient Prefer Adherence 2016; 10: 2181–2187.
30.
Chang SS, Smith JA Jr, Wells N, Peterson M, Kovach B, Cookson MS: Estimated blood loss and transfusion requirements of radical cystectomy. J Urol 2001; 166: 2151–2154.
31.
Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Frank I, Carrasco A, et al.; Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol 2015; 193: 1507–1513.
32.
Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, et al: Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 2014; 120: 2910–2918.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.